Amylyx Pharmaceuticals, Inc.

AMLX

US03237H1014

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
1.83 ^USD	0.00%		+4.27%	-87.57%

14/05	Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating	MT
09/05	Transcript : Amylyx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024

Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 22, 2024 at 06:52 pm IST

Amylyx Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 380.79 million compared to USD 22.23 million a year ago. Net income was USD 49.27 million compared to net loss of USD 198.38 million a year ago.

Basic earnings per share from continuing operations was USD 0.73 compared to basic loss per share from continuing operations of USD 3.39 a year ago. Diluted earnings per share from continuing operations was USD 0.7 compared to diluted loss per share from continuing operations of USD 3.39 a year ago.

Latest news about Amylyx Pharmaceuticals, Inc.

Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating	14/05	MT
Transcript : Amylyx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating	11/04	MT
Transcript : Amylyx Pharmaceuticals, Inc. - Special Call	10/04
Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome	10/04	CI
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $4 From $8, Maintains Buy Rating	05/04	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	04/04	MT
Top Midday Stories: Ford Delays Start of EV Production at Canadian Plant; Alphabet Mulls Acquiring HubSpot; Boeing Paid Alaska Airlines $160 Million in Q1 for Fleet Grounding; Taiwan Semiconductor Expects Full Recovery of Top Plant on Thursday; Coinbase Registered as Restricted Dealer in Canada; CSX Completes First Shipments Using New Rail Post Baltimore Bridge Collapse; Levi Shares Soar on Earnings Beat; Amylyx to Discontinue Marketing Authorizations for Relyvrio	04/04	MT
Amylyx Pharmaceuticals Pulling ALS Drug, Cutting Staff by 70%	04/04	DJ
Amylyx Pharmaceuticals to Discontinue Relyvrio/Albrioza in US, Canada; Slashes Workforce by 70%	04/04	MT
Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market	04/04	CI
Sector Update: Health Care Stocks Edge Up Late Monday Afternoon	19/03	MT
Top Midday Decliners	19/03	MT
Mizuho Downgrades Amylyx Pharmaceuticals to Neutral From Buy After Negative Results From Phase 3 PHEONIX Study, Adjusts PT to $4 From $32	18/03	MT
Amylyx Pharmaceuticals, Inc. Appoints Bernhardt Zeiher to Its Board of Directors	14/03	CI
H.C. Wainwright Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $42, Maintains Buy Rating	12/03	MT
North American Morning Briefing : Inflation Data -2-	12/03	DJ
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $8 From $36, Maintains Buy Rating	11/03	MT
Goldman Sachs Downgrades Amylyx Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $40	11/03	MT
Leerink Partners Downgrades Amylyx Pharmaceuticals to Market Perform From Outperform	11/03	MT
Baird Downgrades Amylyx Pharmaceuticals to Neutral From Outperform, Cuts Price Target to $4 From $37	11/03	MT
North American Morning Briefing : Stock Futures -2-	11/03	DJ
Health Care Flat After Trial Setbacks -- Health Care Roundup	09/03	DJ
Sector Update: Health Care Stocks Ease Late Afternoon	09/03	MT

Chart Amylyx Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). RELYVRIO (also known as AMX0035), an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol is approved to treat ALS in adults in the United States. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.

Sector

Pharmaceuticals

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Amylyx Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.83 USD

Average target price

4.083 USD

Spread / Average Target

+123.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AMYLYX PHARMACEUTICALS, INC.	-87.57%	124M
CSL LIMITED	-2.32%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B
INNOVENT BIOLOGICS, INC.	-6.32%	8.35B

Biopharmaceuticals